CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (Acumen or Acumen Pharmaceuticals) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes…
